Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study.

Loulergue P, Tubach F, Salmon D, Dellamonica P, Taillan B, Thorel JB, Marteau P, Bressot C, Ravaud P, Mariette X, Lortholary O; RATIO Group.

J Infect. 2013 Dec;67(6):524-8. doi: 10.1016/j.jinf.2013.07.027. Epub 2013 Aug 3.

PMID:
23921318
[PubMed - indexed for MEDLINE]
2.

Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.

Tubach F, Ravaud P, Salmon-Céron D, Petitpain N, Brocq O, Grados F, Guillaume JC, Leport J, Roudaut A, Solau-Gervais E, Lemann M, Mariette X, Lortholary O; Recherce Axée sur la Tolérance des Biothérapies Group.

Clin Infect Dis. 2006 Nov 15;43(10):e95-100. Epub 2006 Oct 16.

PMID:
17051484
[PubMed - indexed for MEDLINE]
Free Article
3.

Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.

Inanc N, Direskeneli H.

Rheumatol Int. 2006 Nov;27(1):67-71. Epub 2006 Aug 2.

PMID:
16896990
[PubMed - indexed for MEDLINE]
4.

Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.

Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH.

J Gastroenterol Hepatol. 2010 Nov;25(11):1732-8. doi: 10.1111/j.1440-1746.2010.06407.x.

PMID:
21039834
[PubMed - indexed for MEDLINE]
5.

Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.

Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies Group.

Chest. 2013 Sep;144(3):990-8. doi: 10.1378/chest.12-2820.

PMID:
23744173
[PubMed - indexed for MEDLINE]
6.

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X; RATIO group.

Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.

PMID:
21177290
[PubMed - indexed for MEDLINE]
7.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group.

Arthritis Rheum. 2009 Jul;60(7):1884-94. doi: 10.1002/art.24632. Erratum in: Arthritis Rheum. 2009 Aug;60(8):2540. Lorthololary, O [corrected to Lortholary, O].

PMID:
19565495
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2006 Aug;54(8):2368-76.

PMID:
16868999
[PubMed - indexed for MEDLINE]
Free Article
9.

Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B; Le CRI.

Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.

PMID:
22088934
[PubMed - indexed for MEDLINE]
10.

Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment.

Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, Widmer AF.

J Rheumatol. 2005 Nov;32(11):2125-9.

PMID:
16265689
[PubMed - indexed for MEDLINE]
11.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
[PubMed - indexed for MEDLINE]
12.

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.

Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666.

PMID:
22422487
[PubMed - indexed for MEDLINE]
13.

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.

Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, Romero AB; MIRAR Study Group.

Ann Rheum Dis. 2012 Nov;71(11):1861-4. doi: 10.1136/annrheumdis-2012-201324. Epub 2012 Jun 26.

PMID:
22736086
[PubMed - indexed for MEDLINE]
14.

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

Kroesen S, Widmer AF, Tyndall A, Hasler P.

Rheumatology (Oxford). 2003 May;42(5):617-21.

PMID:
12709536
[PubMed - indexed for MEDLINE]
Free Article
15.

Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.

Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P.

J Rheumatol. 2007 Feb;34(2):380-5. Epub 2006 Oct 1.

PMID:
17013997
[PubMed - indexed for MEDLINE]
16.

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.

Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC; CORRONA Investigators.

Ann Rheum Dis. 2010 Feb;69(2):380-6. doi: 10.1136/ard.2008.089276. Epub 2009 Apr 8.

PMID:
19359261
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.

Davignon JL, Boyer JF, Jamard B, Nigon D, Constantin A, Cantagrel A.

Arthritis Res Ther. 2010;12(4):R142. doi: 10.1186/ar3083. Epub 2010 Jul 15.

PMID:
20633267
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
[PubMed - indexed for MEDLINE]
19.

Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.

Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL.

Mayo Clin Proc. 2001 Jun;76(6):653-6.

PMID:
11393506
[PubMed - indexed for MEDLINE]
20.

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M.

Br J Dermatol. 2007 Mar;156(3):486-91.

PMID:
17300238
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk